Employers search
About Us
About Amyloidosis Research Consortium The Amyloidosis Research Consortium (ARC) is a 501c(3) nonprofit organization founded in 2015, harnessing the power of collaboration and innovation to advance science and both improve and extend the lives of those with Amyloidosis. We are dedicated to transforming the way research is being done and focus on what will have the most significant impact on improving the lives of amyloidosis patients. We forge collaborations across industry, research, clinical care, and regulatory to address unmet needs and accelerate the discovery of new treatments. ARC empowers and supports patients by ensuring they have access to the best quality care and information. ARC now has a staff of 14 professionals, and a $4.5M budget with a Development Team revenue goal for 2026 of $1M. Amyloidosis is a group of diseases where abnormal proteins build up in organs, causing progressive damage. In the U.S., approximately 3,800 new AL amyloidosis cases are diagnosed annually. However, ATTR amyloidosis affects far more people: over 100,000 Americans have the age-related form, and 50,000 people worldwide have the inherited form. Studies show that roughly 13% of older heart failure patients actually have undiagnosed ATTR amyloidosis, meaning the true patient population is even larger. As awareness and diagnosis improve, the community continues to grow. To learn more about ARC, visit http://www.arci.org .